The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541
- Bardia, Aditya
- Hurvitz, Sara A
- Tolaney, Sara M
- Loirat, Delphine
- Punie, Kevin
- Oliveira, Mafalda
- Brufsky, Adam
- Sardesai, Sagar D
- Kalinsky, Kevin
- Zelnak, Amelia B
- Weaver, Robert
- Traina, Tiffany
- Dalenc, Florence
- Aftimos, Philippe
- Lynce, Filipa
- Diab, Sami
- Cortés, Javier
- O’Shaughnessy, Joyce
- Diéras, Véronique
- Ferrario, Cristiano
- Schmid, Peter
- Carey, Lisa A
- Gianni, Luca
- Piccart, Martine J
- Loibl, Sibylle
- Goldenberg, David M
- Hong, Quan
- Olivo, Martin S
- Itri, Loretta M
- Rugo, Hope S
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Bardia, Aditya
- Hurvitz, Sara A
- Tolaney, Sara M
- Loirat, Delphine
- Punie, Kevin
- Oliveira, Mafalda
- Brufsky, Adam
- Sardesai, Sagar D
- Kalinsky, Kevin
- Zelnak, Amelia B
- Weaver, Robert
- Traina, Tiffany
- Dalenc, Florence
- Aftimos, Philippe
- Lynce, Filipa
- Diab, Sami
- Cortés, Javier
- O’Shaughnessy, Joyce
- Diéras, Véronique
- Ferrario, Cristiano
- Schmid, Peter
- Carey, Lisa A
- Gianni, Luca
- Piccart, Martine J
- Loibl, Sibylle
- Goldenberg, David M
- Hong, Quan
- Olivo, Martin S
- Itri, Loretta M
- Rugo, Hope S
- Titel
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- Ist Teil von
- The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with metastatic triple-negative breast cancer were treated with standard chemotherapy or the anti–Trop-2 antibody–drug conjugate sacituzumab govitecan. Patients receiving the drug conjugate had significantly longer progression-free and overall survival as well as more frequent myelotoxic effects and diarrhea.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa2028485Titel-ID: cdi_proquest_miscellaneous_2516842414
- Format
- –
- Schlagworte
- Adult, Adverse events, Aged, Aged, 80 and over, Antibodies, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antigens, Neoplasm, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Breast cancer, Camptothecin - adverse effects, Camptothecin - analogs & derivatives, Camptothecin - therapeutic use, Cancer therapies, Cell Adhesion Molecules - antagonists & inhibitors, Cell surface, Chemotherapy, Confidence intervals, Diarrhea, DNA topoisomerase, Drug Resistance, Neoplasm, Enrollments, FDA approval, Female, Gemcitabine, Humans, Immune Checkpoint Inhibitors - therapeutic use, Immunoconjugates - adverse effects, Immunoconjugates - therapeutic use, Investigations, Leukopenia, Magnetic resonance imaging, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Myelosuppression, Neoplasm Recurrence, Local - drug therapy, Neutropenia, Progression-Free Survival, Survival Analysis, Targeted cancer therapy, Taxanes, Toxicity, Triple Negative Breast Neoplasms - drug therapy, Triple Negative Breast Neoplasms - mortality, Tumor Burden, Vinorelbine, Writers